Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...
Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...
Johnson & Johnson’s stock rose 1.9% early Wednesday, after the medical tech and drug company posted better-than-expected earnings for the fourth quarter, offsetting mixed guidance. The company had per ...
Speaker Mike Johnson (R-La.) on Wednesday said he will establish a new select subcommittee that will probe the Jan. 6, 2021, ...
Reports Q4 revenue $22.5B, consensus $22.45B. “2024 was a transformative year for Johnson & Johnson, marked by strong growth, an ...
Johnson & Johnson (NYSE: JNJ) is proud to announce a Canadian first: the publication of a consensus statement titled, "Optimizing the management of psoriasis in patients with skin of colour: a ...
Johnson & Johnson is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from ...
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...